Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.64 Million EUR | -22.16% |
| 2022 | -6.25 Million EUR | 34.23% |
| 2021 | -9.51 Million EUR | -48.79% |
| 2020 | -6.39 Million EUR | 19.48% |
| 2019 | -7.94 Million EUR | -11.82% |
| 2018 | -7.1 Million EUR | -161.42% |
| 2017 | -2.71 Million EUR | -31.96% |
| 2016 | -2.05 Million EUR | -84.4% |
| 2015 | -1.11 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -225.57 Thousand EUR | 0.0% |
| 2023 Q4 | -3.72 Million EUR | 0.0% |
| 2023 FY | -7.94 Million EUR | -26.94% |
| 2023 Q2 | -4.16 Million EUR | 0.0% |
| 2022 Q4 | -3.07 Million EUR | 0.0% |
| 2022 FY | -6.25 Million EUR | 34.23% |
| 2022 Q2 | -3.59 Million EUR | 0.0% |
| 2021 Q2 | -4.54 Million EUR | 0.0% |
| 2021 FY | -9.51 Million EUR | -48.79% |
| 2021 Q4 | -4.96 Million EUR | 0.0% |
| 2020 Q4 | -2.75 Million EUR | 0.0% |
| 2020 FY | -6.39 Million EUR | 19.48% |
| 2020 Q2 | -3.64 Million EUR | 0.0% |
| 2019 FY | -7.94 Million EUR | -11.82% |
| 2019 Q4 | -3.8 Million EUR | 0.0% |
| 2019 Q2 | -4.14 Million EUR | 0.0% |
| 2018 FY | -7.1 Million EUR | -161.42% |
| 2018 Q4 | -4.09 Million EUR | 0.0% |
| 2018 Q2 | -3.01 Million EUR | 0.0% |
| 2017 FY | -2.71 Million EUR | -31.96% |
| 2017 Q4 | -1.85 Million EUR | 0.0% |
| 2017 Q1 | -679.11 Thousand EUR | 39.22% |
| 2017 Q2 | -868.48 Thousand EUR | -27.88% |
| 2016 Q2 | -941.08 Thousand EUR | -83.13% |
| 2016 FY | -2.05 Million EUR | -84.4% |
| 2016 Q1 | -513.89 Thousand EUR | 0.0% |
| 2016 Q4 | -1.11 Million EUR | 0.0% |
| 2015 Q2 | -276.68 Thousand EUR | 0.0% |
| 2015 Q3 | -276.68 Thousand EUR | 0.0% |
| 2015 Q4 | -513.89 Thousand EUR | -85.74% |
| 2015 FY | -1.11 Million EUR | 0.0% |
| 2015 Q1 | -276.68 Thousand EUR | 0.0% |
| 2014 Q4 | -276.68 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -124.023% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 93.999% |
| Adocia SA | -17.62 Million EUR | 56.624% |
| Aelis Farma SA | -6.46 Million EUR | -18.305% |
| Biophytis S.A. | -14.33 Million EUR | 46.671% |
| Advicenne S.A. | -6.45 Million EUR | -18.378% |
| genOway Société anonyme | 2.06 Million EUR | 470.101% |
| IntegraGen SA | -183.77 Thousand EUR | -4059.371% |
| Medesis Pharma S.A. | -4.22 Million EUR | -80.73% |
| Neovacs S.A. | -6.9 Million EUR | -10.657% |
| NFL Biosciences SA | -4.43 Million EUR | -72.527% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -882.179% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -143.642% |
| Sensorion SA | -22.31 Million EUR | 65.74% |
| TME Pharma N.V. | -5.62 Million EUR | -35.912% |
| Valbiotis SA | -7.16 Million EUR | -6.755% |
| TheraVet SA | -2.17 Million EUR | -251.416% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 62.324% |
| argenx SE | -417.15 Million EUR | 98.168% |
| BioSenic S.A. | -7.04 Million EUR | -8.575% |
| Celyad Oncology SA | -8.45 Million EUR | 9.617% |
| DBV Technologies S.A. | -85.24 Million EUR | 91.033% |
| Galapagos NV | -88.26 Million EUR | 91.34% |
| Genfit S.A. | -26.58 Million EUR | 71.243% |
| GeNeuro SA | -14.35 Million EUR | 46.761% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 52.206% |
| Innate Pharma S.A. | -12.66 Million EUR | 39.666% |
| Inventiva S.A. | -102.7 Million EUR | 92.558% |
| MaaT Pharma SA | -19.94 Million EUR | 61.672% |
| MedinCell S.A. | -20.97 Million EUR | 63.562% |
| Nanobiotix S.A. | -26.77 Million EUR | 71.456% |
| Onward Medical N.V. | -35.46 Million EUR | 78.446% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -68.023% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 66.746% |
| Oxurion NV | -12.11 Million EUR | 36.881% |
| Pharming Group N.V. | -4.87 Million EUR | -56.647% |
| Poxel S.A. | -28.76 Million EUR | 73.426% |
| GenSight Biologics S.A. | -29.69 Million EUR | 74.26% |
| Transgene SA | -30.01 Million EUR | 74.531% |
| Financière de Tubize SA | -2.14 Million EUR | -256.519% |
| UCB SA | 604 Million EUR | 101.266% |
| Valneva SE | -82.08 Million EUR | 90.688% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 73.494% |